According to Geno Germano, a top Wyeth executive, is the bulk of its revenues coming from vaccines and biotech sales rather than from traditional prescription drugs. Over 60% of Wyeth’s 2008 revenues are coming from nonpharmaceutical sources and this percentage is expected to grow with ongoing diversification. Nutritional products, Prevenar (pneumococcal conjugate vaccine), and its biotech drug, Enbrel (etanercept) for rheumatoid arthritis and psoriasis, are the motor behind Wyeth"s growth.